PMID- 20473871
OWN - NLM
STAT- MEDLINE
DCOM- 20110114
LR  - 20211020
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 128
IP  - 3
DP  - 2011 Feb 1
TI  - Plasma insulin-like growth factor 1 is positively associated with low-grade 
      prostate cancer in the Health Professionals Follow-up Study 1993-2004.
PG  - 660-7
LID - 10.1002/ijc.25381 [doi]
AB  - The insulin-like growth factor (IGF) axis plays a role in growth and progression 
      of prostate cancer. High circulating IGF-1 levels have been associated with an 
      increased risk of prostate cancer. Results for IGF binding protein 3 (IGFBP-3) 
      are inconclusive. Some studies have indicated that the positive association with 
      IGF-1 is observed only for low-grade prostate cancer (Gleason sum < 7). We 
      previously reported in the Health Professionals Follow-up Study (HPFS) a direct 
      positive association between ELISA-measured plasma IGF-1 and IGFBP-3 and risk of 
      prostate cancer (462 cases diagnosed after providing a blood specimen (between 
      1993 and 1995), but before February 1998). With additional follow-up through 
      January 31st 2004, and 1,331 case-control pairs in total, we were now able to 
      investigate low-grade (Gleason sum < 7, n = 635) and high-grade (Gleason sum >/= 7, 
      n = 515) prostate cancer separately. Matched odds ratios (OR) and 95% confidence 
      intervals (CI) were estimated using conditional logistic regression. ORs of total 
      prostate cancer comparing top to bottom quartiles were 1.41 (95% CI 1.12-1.78, 
      p-trend = 0.001) for IGF-1 and 1.58 (95% CI 1.24-2.01, p-trend = 0.003) for 
      IGFBP-3. IGF-1 was more strongly associated with low-grade (OR = 1.61 top versus 
      bottom quartile, 95% CI 1.16-2.25, p-trend = 0.01), than with high-grade (OR = 
      1.29, 95% CI 0.89-1.88, p-trend = 0.12) prostate cancer (p-heterogeneity = 0.08). 
      We hypothesize that these findings reflect that high-grade prostate cancers are 
      more autonomous, and, thus, less sensitive to the action of IGF-1 than low-grade 
      cancers.
FAU - Nimptsch, Katharina
AU  - Nimptsch K
AD  - Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA. 
      knimptsc@hsph.harvard.edu
FAU - Platz, Elizabeth A
AU  - Platz EA
FAU - Pollak, Michael N
AU  - Pollak MN
FAU - Kenfield, Stacey A
AU  - Kenfield SA
FAU - Stampfer, Meir J
AU  - Stampfer MJ
FAU - Willett, Walter C
AU  - Willett WC
FAU - Giovannucci, Edward
AU  - Giovannucci E
LA  - eng
GR  - P01 CA055075/CA/NCI NIH HHS/United States
GR  - P30 DK040561-15/DK/NIDDK NIH HHS/United States
GR  - CA55075/CA/NCI NIH HHS/United States
GR  - P01 CA055075-14/CA/NCI NIH HHS/United States
GR  - R01 CA133891/CA/NCI NIH HHS/United States
GR  - P30 DK040561/DK/NIDDK NIH HHS/United States
GR  - CA133891/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Follow-Up Studies
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor I/*analysis
MH  - Male
MH  - Neoplasm Staging
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*blood/pathology/surgery
MH  - Reference Values
PMC - PMC2948057
MID - NIHMS203796
EDAT- 2010/05/18 06:00
MHDA- 2011/01/15 06:00
PMCR- 2012/02/01
CRDT- 2010/05/18 06:00
PHST- 2010/05/18 06:00 [entrez]
PHST- 2010/05/18 06:00 [pubmed]
PHST- 2011/01/15 06:00 [medline]
PHST- 2012/02/01 00:00 [pmc-release]
AID - 10.1002/ijc.25381 [doi]
PST - ppublish
SO  - Int J Cancer. 2011 Feb 1;128(3):660-7. doi: 10.1002/ijc.25381.